Dr. Witta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3501 S Corona St
Ste 1
Englewood, CO 80113Phone+1 303-999-6745Fax+1 303-586-2228
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 2001 - 2004
Northeastern Pennsylvania HospitalsResidency, Internal Medicine, 1998 - 2001
Karlovy University FOMClass of 1990
Certifications & Licensure
NE State Medical License 2024 - 2026
CO State Medical License 2001 - 2025
PA State Medical License 1999 - 2001- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC Start of enrollment: 2008 Jan 08
- A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Publications & Presentations
PubMed
- 9 citationsHistone deacetylase inhibitors in non-small-cell lung cancer.Samir E. Witta
Journal of Thoracic Oncology. 2012-12-01 - 144 citationsRandomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior ChemotherapySamir E. Witta, Robert M. Jotte, Katrik Konduri, Marcus A. Neubauer, Alexander I. Spira
Journal of Clinical Oncology. 2012-04-16 - Santa Monica SupplementSupportive CareSamir E. Witta
Journal of Thoracic Oncology. 2010-12-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
